Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - ProPhase Labs reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
ProPhase Labs announced earnings per share of $0.060 on revenue of $24.2M. Analysts polled by Investing.com EPS of $0.190 on revenue of $18.42M.
ProPhase Labs 's are down 24% and is trading at $9.750 , still down 22.36% from its 52 week high of $15.25 set on Monday, July 11, 2022.
ProPhase Labs shares lost 17.65% to trade at $9.750 in pre-market trade the report.
ProPhase Labs follows other major Healthcare sector earnings this month
ProPhase Labs's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar